| |
|
|
|
|
|
 |
| |
|
Ǫ·Î½ºÅ¸¸óÀÌÁ¤(µð³ëÇÁ·Î½ºÅ溣Ÿ¾¾Å¬·Îµ¦½ºÆ®¸°) PROSTARMON-E TAB.[Dinoprostone]
|
|
Àü¹®ÀǾàǰ | »èÁ¦
|
|
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
642503690[A01506701]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/1Á¤(2007.11.15)(ÇöÀç¾à°¡)
\1,129 ¿ø/1Á¤(2005.08.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
¹é»öÀÇ Á¤Á¦ [Á¦ÇüÁ¤º¸ È®ÀÎ] |
| Æ÷À塤À¯Åë´ÜÀ§ |
30Á¤/°© |
| Æ÷À塤ÄÚµå´ÜÀ§ |
| ¾àǰ±Ô°Ý |
´ÜÀ§ |
Æ÷ÀåÇüÅ |
´ëÇ¥ÄÚµå |
Ç¥ÁØÄÚµå |
ºñ°í |
| 6.67¹Ð¸®±×·¥ |
30 Á¤ |
Åë |
8806425036905 |
8806425036912 |
|
|
| Çã°¡»çÇ× ¿ø¹®Á¶È¸ |
[Çã°¡»çÇ× ¿ø¹®Á¶È¸]
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
ÀӽŸ»±âÀÇ ÁøÅëÀ¯¹ß, ÁøÅëÃËÁø
[Drugbank ÀÇ ¼ººÐÁ¤º¸¿¶÷] [Dinoprostone]
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
[ÁÖ¼ººÐÄÚµå:146301ATB ¿¡ µû¸¥ ½É»çÁöħ¿¶÷]
1. Åë»ó 1ȸ 1Á¤À» 1½Ã°£ °£°ÝÀ¸·Î 6ȸ, 1ÀÏ ÃÑ·® 6Á¤À» (color='#009900'>µð³ëÇÁ·Î½ºÅæÀ¸·Î(3mg)À» 1Kur·Î °æ±¸ Åõ¿©ÇÑ´Ù.
2. üÁß, Áõ»ó, °æ°ú¿¡ µû¶ó ÀûÀÇ Áõ°¨ÇÑ´Ù.
3. ÀÌ ¾àÀÇ Åõ¿© °³½ÃÈÄ ÁøÅëÀ¯¹ß, ºÐ¸¸ÁøÇà È¿°ú¸¦ ÀÎÁ¤ÇÒ ¶§´Â ÀÌ ¾àÀÇ Åõ¿©¸¦ ÁßÁöÇÑ´Ù.
4. 1ÀÏ ÃÑ·® µð³ëÇÁ·Î½ºÅæÀ¸·Î 1Kur, 3mgÀ» Åõ¿©Çϰí È¿°ú°¡ ÀÎÁ¤µÇÁö ¾ÊÀ» °æ¿ì´Â À̾àÀÇ Åõ¿©¸¦ ÁßÁöÇϰí, ´ÙÀ½ ³¯ ¶Ç´Â ±× ÈÄ¿¡ Åõ¿©¸¦ Àç°³ÇÑ´Ù.
|
| ±Ý±â |
- °ñ¹Ý ÇùÂø, ¾ÆµÎ°ñ¹Ý ºÎÀûÇÕ, °ñ¹ÝÀ§µîÀÇ ÅÂÀ§ÀÌ»óÀÌ Àִ ȯÀÚ
- žƿ¡ À§ÇèÀ» ¼ö¹ÝÇÑ´Ù°í »ý°¢µÇ´Â »ê°úÀû ÇÕº´ÁõÀ» °®°í Àִ ȯÀÚ
|
| ½ÅÁßÅõ¿© |
- ³ì³»Àå, ¾È¾ÐÇ×Áø ȯÀÚ
- õ½Ä ¶Ç´Â ±× Àü·ÂÀÌ Àִ ȯÀÚ
- Á¦¿ÕÀý°³ÀÇ Àü·ÂÀÌ Àִ ȯÀÚ
|
| ÀÌ»ó¹ÝÀÀ |
- °ÇÑÁøÅë :
¶§¶§·Î ¸ðü¿¡ °ÇÑ ÁøÅë, žƿ¡ Àý¹Ú°¡»ç ¡ÈÄ (¼¸Æ,ºó¸Æ, ¾ç¼öȥŹ)¸¦ ÀÏÀ¸Å³ ¼ö ÀÖÀ¸¹Ç·Î, °üÂûÀ» ÃæºÐÈ÷ ÇÏ¿© ÀÌ·¯ÇÑ Áõ»óÀÌ ³ªÅ¸³ª´Â °æ¿ì¿¡´Â °¨·® ¶Ç´Â Åõ¿©¸¦ ÁßÁöÇÒ °Í.
¼øÈ¯±â°è : ¶§¶§·Î °æµµÀÇ Ç÷¾Ð»ó½Â, ºó¸ÆÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
Á¤½Å½Å°æ°è : ¶§¶§·Î µÎÅë, Çö¿îÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
¼Òȱâ°è : ¶§¶§·Î °æµµÀÇ ±¸¿ª, ±¸Åä, ¼³»ç°¡ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
ÇǺΰè : ¶§¶§·Î ¾È¸éÈ«Á¶, ¿°¨, ¹ßÇÑÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
±âŸ : ¶§¶§·Î È£ÈíÀÌ»ó, ÈäºÎºÒÄè°¨, µÎÁß, µÎÅëÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
|
| »óÈ£ÀÛ¿ë |
ÀÌ ¾à¿¡ ÀÌ¾î ´Ù¸¥ ÁøÅëÃËÁøÁ¦ (¿Á½ÃÅä½Å, µð³ëÇÁ·Î½ºÆ®µî)À» »ç¿ëÇÏ´Â °æ¿ì¿¡´Â ¾çÁ¦ÀÇ »ó½ÂÈ¿°ú·Î °ÇÑ ÁøÅëÀ» ÀÏÀ¸Å°±â ½¬¿ì¹Ç·Î ÃæºÐÇÑ ºÐ¸¸°¨½Ã¸¦ ÇÏ¸é¼ ½ÅÁßÈ÷ Åõ¿©ÇÒ °Í. |
| Related FDA Approved Drug |
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Cµî±Þ
(Cervical ripeningÀÌ ¹ß°ßµÈ °æ¿ì¸¦ Á¦¿ÜÇϰí, ÀڱþÈÀÇ Å¾ư¡ »ýÁ¸ ´É·ÂÀ» °®Ãß¾úÀ» °æ¿ì¿¡´Â »ç¿ë ±Ý±â )
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ |
[º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| Mechanism of Action |
Dinoprostone¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Dinoprostone administered intravaginally stimulates the myometrium of the gravid uterus to contract in a manner that is similar to the contractions seen in the term uterus during labor, resulting in the evacuation of the products of conception from the uterus.
|
| Pharmacology |
Dinoprostone¿¡ ´ëÇÑ Pharmacology Á¤º¸ Dinoprostone is equivalent to prostaglandin E2 (PGE2). It stimulates labor and delivery and thus terminates pregnancy. Dinoprostone is also capable of stimulating the smooth muscle of the gastrointestinal tract of man. This activity may be responsible for the vomiting and/or diarrhea that is not uncommon when dinoprostone is used to terminate pregnancy.
|
| Metabolism |
Dinoprostone¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Not Available
|
| Protein Binding |
Dinoprostone¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ 73%, to albumin
|
| Half-life |
Dinoprostone¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ Less than 5 minutes.
|
| Absorption |
Dinoprostone¿¡ ´ëÇÑ Absorption Á¤º¸ Absorbed at a rate of 0.3 mg per hour over 12 hours while the vaginal system is in place.
|
| Pharmacokinetics |
DinoprostoneÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- ÀÛ¿ë¹ßÇö½Ã°£ : 10 ºÐ
- ÀÛ¿ëÁö¼Ó½Ã°£ : 2-3 ½Ã°£
- Èí¼ö : ÁúÁ¤ : ¼¼È÷ Èí¼ö
- ´ë»ç : ÁÖ·Î Æó¿¡¼ ´ë»ç
- ¹Ý°¨±â : 2.5-5 ºÐ
- ¼Ò½Ç : ´ë»çü·Î ÁÖ·Î ´¢¹è¼³, ¼Ò·® º¯À¸·Î ¹è¼³
|
| Biotransformation |
Dinoprostone¿¡ ´ëÇÑ Biotransformation Á¤º¸ Rapid metabolism of dinoprostone occurs primarily in the local tissues; any systemic absorption of the medication is cleared mainly in the maternal lungs and, secondarily, at sites such as the liver and kidneys.
|
| Toxicity |
Dinoprostone¿¡ ´ëÇÑ Toxicity Á¤º¸ Oral, mouse: LD50 = 750 mg/kg; Oral, rat: LD50 = 500 mg/kg.
|
| Drug Interactions |
Dinoprostone¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Food Interaction |
Dinoprostone¿¡ ´ëÇÑ Food Interaction Á¤º¸ Not Available
|
| Drug Target |
[Drug Target]
|
| Description |
Dinoprostone¿¡ ´ëÇÑ Description Á¤º¸ Dinoprostone is a naturally occurring prostaglandin E2 (PGE2). It has important effects in labour. It also stimulates osteoblasts to release factors which stimualtes bone resorption by osteoclasts. As a prescription drug it is used as a vaginal suppository, to prepare the cervix for labour and to induce labour.
|
| Dosage Form |
Dinoprostone¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Gel Endocervical (intracervical)Gel IntravaginalInsert IntravaginalTablet Oral
|
| Drug Category |
Dinoprostone¿¡ ´ëÇÑ Drug_Category Á¤º¸ OxytocicsProstaglandins
|
| Smiles String Canonical |
Dinoprostone¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O
|
| Smiles String Isomeric |
Dinoprostone¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O
|
| InChI Identifier |
Dinoprostone¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C20H32O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h4,7,12-13,15-17,19,21,23H,2-3,5-6,8-11,14H2,1H3,(H,24,25)/b7-4-,13-12+/t15-,16+,17+,19+/m0/s1/f/h24H
|
| Chemical IUPAC Name |
Dinoprostone¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ (Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]hept-5-enoic acid
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2021-12-09
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
[ÀǾàǰº´¿ë/¿¬·É´ë±Ý±â °í½Ã±Ù°Å·Î ¹Ù·Î°¡±â] Á¦¸ñ ¾øÀ½
2008³â 8¿ù 1ÀÏ ¾à°¡ÈÀÏ»ó 8¿ù´Þ ½Å±ÔµîÀç ¹× »èÁ¦µÇ´Â ǰ¸ñ Æ÷ÇÔÇÑ º´¿ë¿¬·É ±Ý±â ǰ¸ñ¸®½ºÆ® ±âÁØ
1. ÇöÀç °Ë»öÇÑ Á¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â Á¦Ç° Á¸Àç¿©ºÎ ¹× °Ë»ö
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 Á¦Ç°³»¿ª °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
2. ¿¬·É´ë±Ý±â Á¸Àç¿©ºÎ
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ ¿¬·É±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
|
|
|
|